MTMR10 Inhibitors
MTMR10 inhibitors encompass a variety of chemical compounds that target specific signaling pathways which MTMR10 is associated with, particularly the PI3K/Akt/mTOR pathway. Sirolimus and Rapamycin, for instance, form complexes with FKBP12 that inhibit mTOR, a key kinase within this pathway, leading to potential downregulation of MTMR10, which is thought to engage in endosomal trafficking processes that are influenced by mTOR activity. Similarly, LY294002 and Wortmannin inhibit PI3K directly,which consequently reduces PIP3 production and diminishes Akt signaling, thereby indirectly influencing MTMR10's functionality. Perifosine and Triciribine target Akt more specifically, preventing its activation and subsequent phosphorylation, which could similarly suppress MTMR10's role in relevant cellular processes. GSK690693, another Akt inhibitor, works competitively at the ATP-binding site, and while MTMR10 is not directly part of the Akt pathway, its indirect inhibition could alter MTMR10's activity as it plays a part in Akt-regulated mechanisms.
In addition to Akt pathway inhibitors, MTMR10's activity may also be indirectly modulated by chemicals affecting the MAPK pathway. U0126 and PD98059 both inhibit MEK, which in turn downregulates ERK activity, potentially impacting MTMR10 functions that are implicated in intracellular signaling and trafficking, despite MTMR10 not being directly involved in the MAPK pathway. SP600125 and SB203580 inhibit different MAPK pathway components, JNK, and p38 MAPK, respectively, which could also lead to indirect effects on MTMR10 function due to potential signaling crosstalk. Lastly, the dual mTOR inhibitor PP242 provides a broad inhibition of both mTORC1 and mTORC2, potentially reducing the functional activity of MTMR10 by affecting the entire PI3K/Akt/mTOR signaling cascade, thus illustrating the wide range of indirect mechanisms by which MTMR10 activity can be controlled.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Sirolimus binds to FKBP12 and the complex inhibits mTOR, a kinase involved in cell growth and proliferation. By inhibiting mTOR, downstream targets affecting the PI3K/Akt pathway are influenced, resulting in the indirect inhibition of MTMR10 which is thought to be involved in endosomal trafficking processes regulated by PI3K/Akt. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). Inhibition of PI3K leads to a decrease in PIP3 levels, which in turn reduces Akt phosphorylation and activity. Given that MTMR10 is part of the PI3K-related pathway, its functional activity related to membrane trafficking could be indirectly inhibited through this mechanism. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin irreversibly inhibits PI3K. By decreasing PI3K activity, the production of PIP3 is reduced, leading to diminished Akt signaling. This reduction in the PI3K/Akt pathway activity could indirectly inhibit MTMR10 function, which is associated with the PI3K pathway. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $184.00 $321.00 | 1 | |
Perifosine is an Akt inhibitor that prevents the phosphorylation and activation of Akt. This interference with Akt signaling can indirectly affect MTMR10, considering its likely role in pathways regulated by Akt. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the activation of Akt without affecting PI3K or PDK1. This selective inhibition may lead to a downstream reduction in MTMR10 activity, which is thought to be associated with the Akt pathway. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an ATP-competitive inhibitor of Akt. By inhibiting Akt activity, it could indirectly affect MTMR10, which is implicated in Akt-regulated cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. MTMR10, while not directly involved in the MAPK pathway, might be indirectly impacted by changes in ERK activity, as both are involved in intracellular signaling and trafficking. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, preventing the activation of downstream ERK. Although MTMR10 is not directly linked to the MAPK pathway, inhibiting MEK and thus ERK activity could indirectly affect MTMR10 functions related to signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of JNK, which, like ERK, is part of the broader MAPK pathway. Inhibition of JNK could indirectly affect MTMR10's functional activity due to potential crosstalk between JNK signaling and pathways involving MTMR10. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, it might indirectly modulate MTMR10 activity, potentially affecting cellular processes that MTMR10 is involved with through other signaling pathways. | ||||||